Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Meta-Anal. Feb 3, 2023; 11(2): 47-54
Published online Feb 3, 2023. doi: 10.13105/wjma.v11.i2.47
Published online Feb 3, 2023. doi: 10.13105/wjma.v11.i2.47
Treatment of recurrent hepatocellular carcinoma following liver resection, ablation or liver transplantation
Shalom Z Frager, Department of Medicine, Division of Hepatology, Montefiore Medical Center, Bronx, NY 10467, United States
Weston Cooper, Yvonne Saenger, Cancer Center, Montefiore Medical Center, Bronx, NY 10467, United States
Jonathan M Schwartz, Department of Medicine, Division Hepatology, Montefiore Medical Center, Bronx, NY 10467, United States
Author contributions: Frager SZ wrote a majority of the manuscript; Frager SZ edited the entire manuscript; Cooper W and Saenger Y contributed to the immunotherapy section; Schwartz JM contributed to the liver transplantation sub-section and provided manuscript editing.
Conflict-of-interest statement: All the authors have no conflict of interests to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shalom Z Frager, MD, Staff Physician, Department of Hepatology, Montefiore Medical Center, 111 E 210th St, Bronx, NY 10467, United States.
Received: October 20, 2022
Peer-review started: October 20, 2022
First decision: November 14, 2022
Revised: November 30, 2022
Accepted: January 17, 2023
Article in press: January 17, 2023
Published online: February 3, 2023
Processing time: 104 Days and 13.4 Hours
Peer-review started: October 20, 2022
First decision: November 14, 2022
Revised: November 30, 2022
Accepted: January 17, 2023
Article in press: January 17, 2023
Published online: February 3, 2023
Processing time: 104 Days and 13.4 Hours
Core Tip
Core Tip: Tumor recurrence is frequent following potentially curative modalities for hepatocellular carcinoma. Patients should undergo surveillance imaging following curative treatments and once diagnosed, are potentially eligible for repeat hepatic resection, ablation, trans-arterial embolic therapies, or systemic therapies.